Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Chinese Journal of Lung Cancer ; (12): 66-77, 2023.
Article in Chinese | WPRIM | ID: wpr-971181

ABSTRACT

Immunotherapy has significantly improved clinical outcomes of non-small cell lung cancer (NSCLC), however, along with the popularization of immunotherapy, immune resistance has become an unavoidable problem. Immunotherapy can induce extensive cellular and molecular alterations in the tumor microenvironment. Considering the mechanisms of immune resistance are not yet fully understood and the efficacy of standard chemotherapy regimens is limited, more effective coping strategies based on resistance mechanisms are urgently needed. In this review, we intend to summarize the known mechanisms of immune resistance and feasible strategies, so as to provide a foundation for clinicians to develop more individualized and precise regimens and finally improve patients' prognosis.
.


Subject(s)
Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Prognosis , Immunotherapy , Tumor Microenvironment
2.
Chinese Journal of Lung Cancer ; (12): 653-659, 2021.
Article in Chinese | WPRIM | ID: wpr-888590

ABSTRACT

Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer severely affects the quality of life and prognosis of patients. Tumor-associated genetic testing is the basis for making precise treatment decisions. There are some risks of tissue biopsy, and it is difficult to sample repeatedly. Due to its non-invasive and can reflect the full profile of tumor gene characteristics, liquid biopsy is increasingly used in the diagnosis and treatment of lung cancer. Because of the extremely low DNA level of circulating tumor, the sensitivity and specificity of liquid biopsy based on blood samples are limited. Tumor cells is enriched in MPE. The detection of cell-free DNA, extracellular vesicles and microRNA in MPE will be helpful to the diagnose, treatment and assess prognosis of patients with lung cancer. This review aims to discuss the research progress of liquid biopsy based on MPE in the diagnosis and treatment of lung cancer patients.
.

3.
Chinese Journal of Medical Education Research ; (12): 558-562, 2020.
Article in Chinese | WPRIM | ID: wpr-865846

ABSTRACT

There are two methods of endoscopic teaching including traditional apprenticeship mode and simulation training. Although the apprenticeship model has some advantages in the docking of experience, there are many shortcomings. Virtual reality simulation training is learner-centered in endoscopic teaching, which is a safe and effective training method and an important supplement to the apprenticeship model. In the process of simulation training, paying attention to feedback, obtaining non-technical ability, dealing with emergencies in endoscopic operation and optimizing ergonomics are the directions of future research. This paper will briefly summarize the research progress of virtual reality simulation training in endoscope teaching.

4.
Chinese Journal of Lung Cancer ; (12): 118-124, 2019.
Article in Chinese | WPRIM | ID: wpr-775655

ABSTRACT

Lung cancer is the most commonly diagnosed cancer worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer seriously affect the patients' quality of life and prognosis. The management of MPE includes thoracentesis, pleurodesis, indwelling pleural catheters and drug perfusion in pleural cavity. Vascular endothelial growth factor (VEGF) and its receptor are a group of important ligands and receptors that affect angiogenesis. They are the main factors controlling angiogenesis, and they play an important role in the formation of MPE. Bevacizumab is a recombinant humanized VEGF monoclonal antibody, competitively binding to endogenous VEGF receptor. Bevacizumab can inhibit new blood vessel formation, reduce vascular permeability, prevent pleural effusion accumulation and slow the growth of cancers. This review aims to discuss the progress of bevacizumab in the treatment of MPE caused by non-small cell lung cancer (NSCLC), and explore the clinical application, efficacy, safety and future direction of bevacizumab.
.


Subject(s)
Humans , Antineoplastic Agents , Therapeutic Uses , Antineoplastic Agents, Immunological , Therapeutic Uses , Carcinoma, Non-Small-Cell Lung , Pathology , Pleural Effusion, Malignant , Drug Therapy , Pleural Neoplasms , Drug Therapy
SELECTION OF CITATIONS
SEARCH DETAIL